Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

RedHill Biopharma (RDHL) Change in Intangibles (2016 - 2020)

RedHill Biopharma has reported Change in Intangibles over the past 7 years, most recently at -$735000.0 for Q3 2020.

Quarterly Change in Intangibles changed N/A to -$735000.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was -$52.8 million through Dec 2020, changed N/A year-over-year, with the annual reading at -$53.4 million for FY2020, 152380.0% down from the prior year.
Change in Intangibles was -$735000.0 for Q3 2020 at RedHill Biopharma, up from -$52.5 million in the prior quarter.
Over five years, Change in Intangibles peaked at $465000.0 in Q4 2018 and troughed at -$52.5 million in Q2 2020.
The 4-year median for Change in Intangibles is -$617500.0 (2018), against an average of -$9.1 million.